Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares have increased modestly, although the company’s latest news flow is dominated by regulatory uncertainty and legal risks. The key developments are an extension of the FDA review for deramiocel and a wave of investor alerts concerning a securities class action.

• Negative Sentiment: An analyst reportedly downgraded Capricor to “Hold,” citing the FDA’s extension of the review period for deramiocel and changes related to the Duchenne muscular dystrophy program. The delay pushes out a potential regulatory catalyst and may increase uncertainty surrounding the therapy’s approval timeline. Capricor Downgrade to Hold on Deramiocel PDUFA Extension and DMD Change
• Negative Sentiment: Multiple law firms publicized an existing securities class action against Capricor Therapeutics, alleging violations of federal securities laws and misstatements related to clinical data, including the HOPE-3 trial. The alleged class period runs from December 17, 2025, through July 26, 2026, with September 28, 2026, set as the deadline for investors to seek lead-plaintiff status. These announcements do not represent separate confirmed findings, but they highlight potential litigation costs, reputational damage and disclosure risk for CAPR. Rosen Capricor Securities Class Action Deadline
• Neutral Sentiment: The numerous September 3–4 investor notices largely repeat the same class-action deadline and encourage affected shareholders to contact plaintiffs’ firms. They provide little new information about Capricor’s operating performance or deramiocel’s clinical prospects, so the immediate stock impact is likely driven more by the FDA review delay and litigation overhang than by the notices themselves. Kaplan Fox Capricor Investor Notice